Dara Biosciences (DARA) 0.88 $DARA DARA BioSciences wins

New Post Public Reply Private Reply Replies (0) Message Board

Jun 12, 2016 at 2:02 AM

Dara Biosciences (DARA) 0.88 $DARA

DARA BioSciences wins stockholder's approval of merger with and into Midatech
M2 - Thu Dec 03, 5:27AM CST
DARA BioSciences (NasdaqCM

ARA) reported on Wednesday the receipt of stockholders' approval for the adoption of the merger agreement by and among DARA, Midatech Pharma PLC (Midatech) and certain other parties thereto.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Stockholder Approval of Merger With Midatech
Marketwired - Wed Dec 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that its stockholders have approved the adoption of the previously announced merger agreement by and among DARA, Midatech Pharma PLC ("Midatech"

and certain other parties thereto.
DARA: 0.88 (-0.06)

DARA BioSciences posts higher loss of USD2.7m for Q3 2015
M2 - Tue Nov 03, 4:21AM CST
Pharmaceutical company DARA BioSciences (NasdaqCM

ARA) disclosed on Monday that it recorded a loss attributable to controlling interest of approximately USD2.7m (USD0.14 per share) for the third quarter ended 30 September 2015.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Third Quarter 2015 Results
Marketwired - Mon Nov 02, 3:30PM CST
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its third quarter 2015 results.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the 2015 Aegis Growth Conference on October 8, 2015
Marketwired - Tue Oct 06, 7:02AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA) today announced that it will be featured as a presenting company at the 2015 Aegis Growth Conference, sponsored by Aegis Capital Corp. The Aegis Growth Conference, which will feature growth companies in Healthcare, Technology, Telecom and Aerospace-Defense sectors, will be held October 7-9, 2015 at The Encore at Wynn Hotel in Las Vegas, NV. DARA BioSciences is an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment.
DARA: 0.88 (-0.06)

DARA BioSciences unveils Oravig (miconazole) in the oncology and primary care markets in the US for treatment of adults with oral thrush
M2 - Tue Oct 06, 4:36AM CDT
Specialist pharmaceutical company DARA BioSciences (NasdaqCM

ARA) reported on Monday the availability of Oravig, the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush, into the oncology and primary care markets in the US.
DARA: 0.88 (-0.06)

DARA BioSciences Announces U.S. Launch of Oravig(R) (miconazole), the First and Only Orally-Dissolving Buccal Tablet Available for Treatment of Adults With Oral Thrush
Marketwired - Mon Oct 05, 7:01AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care specialty pharmaceutical company dedicated to providing healthcare professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatments, announced today the U.S. launch of Oravig -- the first and only orally-dissolving muco-adhesive buccal tablet approved to treat adults with oral thrush -- into the Oncology and Primary Care markets. Beginning this week, DARA and its marketing partner Mission Pharmacal Company, a privately held pharmaceutical company based in San Antonio, TX, will simultaneously begin promotion of Oravig with two separate sales forces focusing on the highest prescribing physicians of oral thrush therapy; DARA will promote Oravig exclusively in Oncology with its 20 person nationwide sales force and Mission will utilize its 40 person-strong sales team to promote the product exclusively to the Primary Care market. DARA was granted exclusive U.S. rights to Oravig in March 2015, under a Commercialization Agreement with Onxeo S.A., an innovative company specializing in the development of orphan oncology drugs.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the Ladenburg Thalmann 2015 Healthcare Conference on September 29, 2015
Marketwired - Wed Sep 23, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Ladenburg Thalmann 2015 Healthcare conference. The conference is being held September 29, 2015, at the Sofitel Hotel in New York City.
DARA: 0.88 (-0.06)

DARA BioSciences to Present at the 17th Annual Rodman and Renshaw Global Investment Conference on September 9, 2015
Marketwired - Wed Sep 02, 3:30PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will be featured as a presenting company at the Rodman and Renshaw Global Investment Conference. The conference is being held September 8-10, 2015, at the Saint Regis Hotel in New York City.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Second Quarter 2015 Results
Marketwired - Wed Aug 12, 3:15PM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced its second quarter 2015 results.
DARA: 0.88 (-0.06)

DARA BioSciences Announces Date and Time for Announcement of Second Quarter 2015 Results
Marketwired - Mon Aug 10, 7:00AM CDT
DARA BioSciences, Inc. (NASDAQ: DARA), an oncology supportive care pharmaceutical company dedicated to providing health care professionals a synergistic portfolio of medicines to help cancer patients adhere to their therapy and manage side effects arising from their cancer treatment, today announced that it will release financial results for the second quarter ended June 30, 2015, after the close of the market on Wednesday, August 12, 2015.
DARA: 0.88 (-0.06)

Robbins Arroyo LLP: Acquisition of DARA BioSciences, Inc. (DARA) by Midatech Pharma Plc (MTPH) May Not Be in Shareholders' Best Interests
PR Newswire - Thu Jun 25, 2:49PM CDT
Shareholder rights attorneys at Robbins Arroyo LLP are investigating the proposed acquisition of DARA BioSciences Inc. (NASDAQ: DARA) by Midatech Pharma Plc (London: MTPH). On June 4, 2015, the two companies announced the signing of a definitive merger agreement pursuant to which Midatech will acquire DARA. Under the terms of the agreement, DARA shareholders will receive 0.272 shares of Midatech for each share of DARA they own, the value of which is equivalent to $1.20 per share of DARA common stock.
DARA: 0.88 (-0.06)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Michaels' Countdown to Craftsmas: Screen-Free Holiday Offer

Crafting Memories over Clicking Screens The holidays are supposed to be about making memories, right? Well, Michaels is banking on that idea by pulling people away from their screens and nudging them into a hands-on world with its "Countdown to Craftsmas" advent calendar. Starting November 27, they’re tossing in a freebie that’s packing some crafty punches — just...

Abbisko's PIMJETMI® Gains FDA Nod, Boosting TGCT Treatment

PIMJETMI® Scores FDA Approval, Expanding Global Reach Well, here's something to chew on over your morning coffee—PIMJETMI® (pimicotinib) just snagged the U.S. FDA's blessing to treat tenosynovial giant cell tumor (TGCT), making it another notch on Abbisko Therapeutics' belt. This approval is a strategic home run for Abbisko and their pals at Merck KGaA, Darmstadt,...

Cepheid Expands Diagnostic Potential with IVDR Approval

A Key Milestone for Cepheid Breathing new life into Europe's diagnostic landscape, Cepheid's Xpert Respiratory Panel just snagged the CE marking under the IVDR. This ain't just some technical checkbox; this test's got the goods to spot 13 respiratory pathogens from one measly swab. It's a hefty lineup—think Adenovirus, different flavors of flu, and even the sneaky...

Supermetrics Debuts AI Campaign Manager for Marketers

These days, digital marketing feels like trying to build a puzzle in a sandstorm. You've got all these pieces flying around, valuable insights buried somewhere in the mix, and you can't just toss 'em together however you like. Supermetrics steps into this whirlwind with their new tool, Campaign Manager, promising marketers a direct line from insight to action. Finally, a...

The DOG CATCHER: A New Spin on Pet Waste Cleanup

Revolutionizing the Dreaded Pet Waste Duty Folks, here's a little dose of innovation from the streets of Baltimore: a gadget called the DOG CATCHER. No, it’s not about catching stray dogs, but dealing with their unpleasant leavings. This invention's got a patent pending and all, promising to make the nasty business of dog waste collection a whole lot less disgusting. I...

Bybit Enhances Copy Trading with Fine-Tuned Filters

Fine-tuning in the Wild West of Copy Trading Pull up a chair, because this is one for the books. Bybit, that sprawling new financial playground trusted by 80 million folks around the globe, just laid another stone on the path to trading enlightenment with their Copy Trading Classic. They’ve cranked up the ability to sift through Master Traders like a prospector panning...

Alyssa Bunch: Big Moves in Tennessee Real Estate

Navigating the Tennessee Real Estate Maze If you're talking about where the real estate action happens in Tennessee, you'd better mention Alyssa Bunch, the Vanderbilt-educated dynamo who turns the unforsale into the must-buy. Most of the deals she orchestrates are invisible to the public eye until they're all but written in ink and ready to reshape landscapes—or, more...

Braemar's $358 Million Refinance: A Strategic Shift

Reworking the Debt Load: Braemar's New Move Most days, when a company decides to tinker with its debt, it's like watching paint dry for investors. But with Braemar Hotels & Resorts (NYSE: BHR) announcing a $358 million refinancing package, they're bringing a fresh breath of air to the table. Lemme walk you through why this matters beyond the glossy façade of luxury hotel...

Centrus Energy Welcomes Nuclear Veteran to Leadership

Navigating a New Era at Centrus When you hear about seasoned veterans stepping up to the plate in the energy sector, it's time to perk up your ears. Centrus Energy (NYSE:LEU), a big player in nuclear fuel, just added Kevin Graney to their Board of Directors. This isn't your run-of-the-mill appointment; it packs nearly three decades of nuclear tech and national security...

Retail's AI Ambitions Clash with In-Store Data Realities

AI's Lofty Goals Meet Retail's Messy Reality I swear, all this chatter about AI transforming retail sounds grand until you dig into the messy trenches, right? This latest Scandit survey lays it bare: retailers have got their AI visions sprinting ahead of the stock data realities inside their stores. Seems those shiny new systems rely on stock data that matches what's...